With an increasing number of cancer profi ling studies assaying both transcript mRNA and copy number expression levels, a natural question then involves the potential to combine information across the two types of genomic data. In this article, we perform a study to assess the nature of association between the two types of data across several experiments. We report on several interesting fi ndings: 1) global correlation between gene expression and copy number is relatively weak but consistent across studies; 2) there is strong evidence for a cis-dosage effect of copy number on gene expression; 3) segmenting the copy number levels helps to improve correlations.
Introduction
With the explosion of high-throughput technologies for measuring various aspects of molecular activity, it has become possible to globally monitor the biochemical activities of cells. Much of the application of these technologies has been in the area of cancer, one major example of which is transcript mRNA microarrays (Schena, 2002) . There is now a vast literature on microarray studies done in cancer; a simple PubMed search of the phrase "microarray data, cancer" turns up approximately 2400 entries, 99% of which have been published since 2000.
While there have been many examples of individual molecules, genomic signatures and pathways that have been discovered as being dysregulated in cancer through analyses of gene expression data, a more promising avenue is arising based on consideration of integrating genomic data sources in order to validate previous fi ndings based on gene expression studies and to decipher higher-order modular mechanisms of co-expressed genes enriched in various molecular pathways (Rhodes and Chinnaiyan, 2005; Segal et al. 2005) .
In cancer, chromosomal aberrations occur frequently. Various types of cytogenetic aberrations, including segmental amplifi cation/deletion and unbalanced translocation events, are a major characteristic of the majority of epithelial tumors. These complex transformations lead to activation of oncogenes and inactivation of tumor suppressor genes. There are many examples of genes that undergo amplifi cations in cancer, including AKT2 in ovarian cancer, ERRB2 in breast and ovarian cancer, MYCL1 in small cell lung cancer, MYCN in neuroblastoma and EGFR in glioma and non-small cell lung cancer; a comprehensive account of these and other cancer-related genes can be found in Futreal et al. (2004) . It has also been shown that many of these changes correlate with clinical factors, such as survival, stage and response to treatment. As an example, for metastatic breast cancer patients with the ERBB2 gene amplifi cation, trastuzumab (Herceptin) is a targeted therapy that is available to achieve a better prognosis.
There are now studies in which microarray data on both an mRNA transcript level as well as a copy number level are being collected. As demonstrated in Virtaneva et al. (2001) , a correlation exists between copy number and gene expression in cancer. There are other potential advantages to the integration of copy number and gene expression data. Ludwig and Weinstein (2005) write that the integration of mRNA transcript and copy number information could lead to the identifi cation of new biomarkers. Similarly, Myllykangas and Knuutila (2006) write that integration of copy number and gene expression data can potentially be used to "understand the effects of gene regulation and transcription in amplifi cation manifestation." With the recently funded Cancer Genome Atlas (http://cancergenome.nih.gov), multiple levels of genomic data are being collected on tumor samples. This will be a valuable resource to the cancer research community. A key question then will be how to combine such genomic datasets.
While there are currently few studies in which both transcript mRNA and copy number microarrays are collected on matched samples, we give two examples which have yielded promising results. In a study by Garraway et al. (2005) , the authors examined Affymetrix SNP array data generated on the celebrated NCI-60 cell line data and then sought to fi nd alterations between tissuespecifi c cancers. Based on such differences, they then looked for differentially expressed genes in the regions that showed overamplifi cation in the corresponding cell lines. These analyses implicated a new candidate oncogene, MITF. In another study using copy number and gene expression study data from the NCI 60 cell line dataset, Bussey et al. (2006) explored the behavior of 64 candidate oncogenes based on correlations between gene expression, copy number and compound activity score. Based on these correlations, they were able to nominate some candidate biomarkers. We term studies of this type as being in the area of cancer "integromics,'' where data measuring different biochemical activities are measured on the same samples. They demonstrate the potential of such datasets to better identify candidate biomarkers in disease progression and prognosis.
In this study, global associations between gene expression and copy number are examined across studies of multiple cancer types. This analysis was motivated for the following reasons. First, knowing the general pattern of correlation structure between the two data types allows us to assess the feasibility of integrative analysis in terms of expected (within-sample) signal-to-noise ratio and variability of the association between copy number and gene expression across samples. Second, it is important to know if the correlation between gene expression and copy number generalizes across different sites of origin. Third, correlation between the two types of data may differ by the nature of samples. In particular, copy number characterization will be distinct depending on whether the study is in vivo or in vitro. Much of the results reported will be of a descriptive nature. Finally, we will explore higher-order correlations using modern machine learning methodologies (Efron et al. 2004 ) as well as bioinformatic methods for segmenting genomic data (Olshen et al. 2004 ).
Methods

Datasets
Only genomic datasets in which the same samples were profi led on a genomic DNA and transcriptomic basis using two-channel microarray platforms were considered here. Use of the same array (probe) designs on both data types avoids having to perform inter-platform identifi cation mapping of genes.
We searched the Stanford microarray database (http://genome-www5.stanford.edu/), Gene Expression Omnibus ( (2005) and Kim et al. (2006) . Here and in the sequel, we will refer to these datasets by the name of the fi rst author. There are three things we note about the datasets. First, all of the datasets except for that from Pollack et al. (2002) are from cancer cell lines. Second, the cell lines are from different tissues of origin. This will allow us to observe tissue-specific phenomena. Third, the Hyman et al. (2002) and Pollack et al. (2002) breast datasets will allow us to assess concordance of copy number/transcript correlations between in vivo and in vitro systems.
Data Preprocessing
Missing data were imputed using a k-nearest neighbors algorithm with k = 5 (Troyanskaya et al. 2001 ). Then, a variance fi lter was applied to the transcript mRNA and copy number microarray datasets separately. The spots with the lowest 25% variance across all samples were excluded from each dataset. This was done to ensure that the correlations calculated in the study would not be subject to artefacts arising from experimental noise. The fi nal numbers of genes and samples from the available studies are listed in Table 1 .
Results
Univariate correlation study
As an initial analysis, we calculated Pearson correlation between the expression level of every gene with its corresponding copy number expression profi le. This is shown in Table 2 .
Comparing the median values for correlation between transcript mRNA and copy number across the fi ve studies is equivalent to the copy number explaining 12%-40% of the variation in gene expression across the fi ve studies. Compared to the 12% fi gure given by Pollack et al. (2002) , we fi nd evidence of stronger association in the cell line datasets than in the human tissue. In general, we fi nd weak correlation globally between the transcript mRNA and copy number expression levels. However, on average, we can also say that the correlation distribution appears fairly consistent across studies, with the one exception being the Zhao et al. study, which appears to have a greater amount of variability than the other studies. This is probably due to the small sample size of the study; it has the lowest number of samples among the studies.
We next summarized all possible pairwise univariate correlations between gene expression and copy number. The results are given in Table 3 .The correlation between a gene's expression level and corresponding copy number rarely represents the largest correlation in terms of magnitude in the dataset. Table 3 suggests that there tends to be stronger correlation between transcript levels and copy number if we consider genes from the same chromosome; however, the increase in the proportion of genes with high correlation remains modest. This is a consistent fi nding with the notion of regulation of gene expression not being a simple relationship. It is also suggestive of a so-called "cis-dosage'' effect of copy number on transcription. We further explored this association using more modern data mining techniques in the next section.
Higher-order correlation studies
While Table 1 provides a nice summary of the univariate correlations, we also explored higherorder correlation modelling strategies. In particular, we wished to allow for the effects of copy number expression from multiple loci to infl uence the transcription level of a gene.
The approach we tried was Least Angle Regression ("LARS") (Efron et al. 2004) . It involves fi tting a linear regression model in which the response variable is gene expression and the copy number expression values from all loci are potential predictors. Since the possible number of predictors is much greater than the number of samples, it is impossible to obtain a unique estimate of the linear regression model. The LARS algorithm allows the user to fi t such a model; its estimation procedure involves a sequential and iterative fi tting procedure where only m sequential steps are taken. In our case, we take m = (number of samples)/2. This implies that a large fraction of the regression coeffi cients will be estimated to be exactly zero. Below is a description of the LARS procedure:
1. All coeffi cients are equal to zero at the beginning, fi nd the predictor most correlated with the response, denote as x j1 . 2. With x j1 we fi nd x j2 which is most correlated with the current residual vector. 3. Proceed equiangularly between the two predictors until a third covariate x j3 enters the "most correlated" set. 4. Proceed equiangularly between x j1, x j21 and x j3 until the fourth covariate enters, and so on.
After m steps, we stop. Thus in the fi nal results of the regression, for each response there are only m covariates have non-zero estimated coeffi cients. Such an approach allows for multiple copy number expression values to influence a given gene's mRNA transcript levels.
Given the results of the LARS analyses for each gene, we can test for a cis-dosage effect. If such an effect exists, then this means that the mRNA expression of one gene is more correlated with the DNA copy number of genes located on the same chromosome than with DNA copy number of genes from different chromosomes. We tested for the presence of a cis-dosage effect using a Wilcoxon test. These results are summarized in Supplementary Table 1 .
We draw several conclusions from the table. First, the strength of the cis-dosage effect varies across cancer type. For the purposes of interpreting the table, if we assumed that there was no cis-dosage effect globally, we still would expect approximately one chromosome to show significant evidence of a cis-dosage effect if we are testing at a signifi cance level of 0.05. It is most signifi cant for breast cancer, showing twenty signifi cant chromosomes for the Pollack et al. data and 16 significant chromosomes for the Hyman et al. (2002) data. However, for the prostate cancer cell line there only exist 9 signifi cant chromosomes. The correlation patterns for cancer tumor tissue and cell lines from the Pollack and Hyman et al. data, which are both from breast cancer, are similar in that both show strong overall location effect. In conclusion, based on our analysis, the relationship between copy number and expression level is appears to be greater than captured by simple correlation, and the significance of this relationship varies for different cancer types.
The other correlation analysis we performed was to take into account that copy number and gene expression levels might have spatial correlation. This is accommodated through the use of segmentation techniques (Olshen et al. 2004 ). In particular, we repeated the correlation of analysis in Table 2 by segmenting both the copy number and the gene expression data. Various correlations were calculated and are summarized in Table 4 . This table shows that the single gene copy numbertranscript mRNA correlations improve by incorporating segmentation methods into the analysis. This also suggests that incorporating the spatial correlation in gene expression and copy number expression will improve the amount of gene expression variation that is explained by copy number expression.
Discussion
In this study, we have explored the nature of correlation between transcript mRNA and copy number for genes across fi ve cancer profi ling studies in which both types of measurements were collected on the same samples. Three fi ndings are notable from this study:
1. The global nature of correlation between transcript mRNA and copy number is in accordance with what is reported in Pollack et al. (2002) and appear to be consistent across studies. 2. There is solid evidence for a cis-dosage effect of copy number on transcription. 3. Segmentation of genomic data leads to better correlation, even more than what has been suggested by Pollack et al. Notes: In this table, the second column refers to the number of genes in which the largest correlation in magnitude with copy number is that from the same gene (i.e. the same spot on the microarray). The third column refers to the number of genes whose largest correlation between expression and copy number was with a spot that mapped to a gene on the same chromosome.
The fi rst result suggests that other phenomena might control and hence be able to explain the variation in gene expression. Examples include histone modifi cations, mutations in DNA sequence, microRNA molecules and protein activity. This study outlines that there are still many factors that are needed to explain gene expression. With the explosion in new technologies, the effects of other factors on gene expression could potentially be studied. A second and more statistical point is that the weak overall correlation suggests that the approach authors have taken of focusing on specifi c genes or molecules from "integromic'' analyses of gene expression and copy number data seem to be quite reasonable. If there were stronger correlations between gene expression and copy number, then there would be potential advantage in pooling results from spatially contiguous genes; however, this approach might not lead to any gains in power, given the nature of correlation that we are fi nding here.
Of course, if there are sample-specifi c artefacts, then using the correlation coeffi cient across samples might lead to erroneous conclusions.
One major limitation of our study is that we are not considering clinically heterogeneous samples at all, i.e. we treat each study as having samples coming from one population. With samples from the Cancer Genome Atlas, there will be linked clinical information to the genomic data. It might be the case that the nature of correlation will change depending on certain clinical parameters. This was the approach implicitly utilized by Bussey et al. (2006) and is potentially powerful for fi nding new biomarkers. How to incorporate clinical information into the analysis is an open area of research and is currently under investigation.
Much of the results we have reported have been based on descriptive measures. A challenging issue is how to perform statistical inference. While permutation procedures are quite popular, it is not Notes: SD represents standard deviation; MAD represents mean absolute deviation. Both Unsegmented refers to correlation coeffi cients between gene expression and copy number based on the raw expression number value, after taking the preprocessing steps described in the paper. Expression Segmented refers to running the algorithm of Olshen et al. (2004) on the gene expression data on individual samples and to then calculate the correlation coeffi cients between gene expression and copy number expression. Copynumber Segmented refers to running the algorithm of Olshen et al. (2004) on the copy number expression data on individual samples and to then calculate the correlation coeffi cients between gene expression and copy number expression. Both Segmented refers to running the algorithm of Olshen et al. (2004) on the copy number and gene expression data on individual samples and to then calculate the correlation coeffi cients between gene expression and copy number expression.
clear what should be permuted. In addition, if one wishes to incorporate spatial dependence, then clearly a model-based approach is needed. Finally, this should be viewed as an initial study in the area. With the possibility of larger-sized datasets emerging in the future, the nature of copy number and gene expression will be more reliably assessed. By fi nding consistent patterns across the individual datasets, this provides some strength of evidence to our study. Table S1 . Results of the LARS analyses to fi nd cis-dosage effects of copy number on gene expression. The results are grouped by fi rst study author. Chrm refers to chromosome. Average number of non-zero betas denotes the average number of copy number expression measurements from the same chromosome found to have a non-zero effect on gene expression for all genes on the chromosome. Expected number of non-zero betas denotes the average number of non-zero betas under the null hypothesis of no-cis dosage effect. P-value is based on the Wilcoxon rank-sum test.
